Mycenax Biotech (4726) - Total Liabilities
Based on the latest financial reports, Mycenax Biotech (4726) has total liabilities worth NT$1.69 Billion TWD (≈ $53.13 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 4726 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Mycenax Biotech - Total Liabilities Trend (2017–2024)
This chart illustrates how Mycenax Biotech's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Mycenax Biotech balance sheet assets.
Mycenax Biotech Competitors by Total Liabilities
The table below lists competitors of Mycenax Biotech ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
IZMO Limited
NSE:IZMO
|
India | Rs848.53 Million |
|
Maple Gold Mines Ltd
V:MGM
|
Canada | CA$5.80 Million |
|
Paxman AB
ST:PAX
|
Sweden | Skr59.89 Million |
|
Alicanto Minerals Ltd
AU:AQI
|
Australia | AU$692.69K |
|
T&L Co. Ltd
KQ:340570
|
Korea | ₩20.08 Billion |
|
i-SENS Inc
KQ:099190
|
Korea | ₩234.55 Billion |
|
Hope Education Group Co. Ltd
F:HE1
|
Germany | €8.01 Billion |
|
Wanhwa Enterprise Co
TW:2701
|
Taiwan | NT$1.39 Billion |
Liability Composition Analysis (2017–2024)
This chart breaks down Mycenax Biotech's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Mycenax Biotech (4726) balance sheet quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.75 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.51 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Mycenax Biotech's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Mycenax Biotech (2017–2024)
The table below shows the annual total liabilities of Mycenax Biotech from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$1.34 Billion ≈ $42.37 Million |
+1.64% |
| 2023-12-31 | NT$1.32 Billion ≈ $41.69 Million |
-1.80% |
| 2022-12-31 | NT$1.35 Billion ≈ $42.45 Million |
+9.34% |
| 2021-12-31 | NT$1.23 Billion ≈ $38.83 Million |
+127.84% |
| 2020-12-31 | NT$540.89 Million ≈ $17.04 Million |
+76.74% |
| 2019-12-31 | NT$306.04 Million ≈ $9.64 Million |
+44.56% |
| 2018-12-31 | NT$211.70 Million ≈ $6.67 Million |
+25.32% |
| 2017-12-31 | NT$168.93 Million ≈ $5.32 Million |
-- |
About Mycenax Biotech
Mycenax Biotech Inc. provides biopharmaceutical services and solutions for drug development and production in Taiwan. The company's services include program evaluation/confirmation, cell line development and construction, process development technology platforms, drug characterization analysis, establishment of testing methods, and PIC/S GMP drug production. It offers plasmid DNA, antibody-drug c… Read more